Le Lézard
Classified in: Health, Science and technology
Subject: Conference

Analysis of Newly Expanded Cumulative Cohort Demonstrates that DecisionDx-Melanoma Improves Risk Prediction for Patients with Cutaneous Melanoma


Castle Biosciences, Inc., a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced the presentation of newly expanded performance results for DecisionDx®-Melanoma at the 2019 Fall Clinical Dermatology Conference for PAs & NPs held in Scottsdale, Arizona. The poster, titled "The prognostic 31-gene expression profile (31-GEP) test improves risk prediction in cutaneous melanoma (CM) patients within current AJCC stages," demonstrated the utility of DecisionDx-Melanoma in identifying risk for patients with cutaneous melanoma beyond traditional staging.

Using a newly expanded performance cohort of 901 archival cutaneous melanoma samples (211 of which were not previously reported) from 22 centers, the analysis was designed to examine whether incorporating the DecisionDx-Melanoma test result in treatment decisions improves upon traditional melanoma staging methods. Patients assessed in the expanded cohort had a median age of 60 years and a median Breslow thickness of 1.4 mm. Forty-four percent of melanomas were American Joint Committee on Cancer (AJCC) Stage I, 24% were Stage II and 32% were Stage III.

Key Study Findings

"Accurate risk assessment in cutaneous melanoma is important because most treatment decisions are based on the patient's expected risk of metastasis or recurrence," commented study co-author Darrell S. Rigel, M.D., M.S., Clinical Professor at New York University School of Medicine. "These results show that DecisionDx-Melanoma provided a more comprehensive assessment of patient risk compared to AJCC staging alone, supporting its utility in developing individualized patient management plans."

The poster can be found in the Publications section of the Castle Biosciences website.

About DecisionDx-Melanoma

DecisionDx-Melanoma is a gene expression profile test that uses an individual patient's tumor biology to predict individual risk of cutaneous melanoma metastasis or recurrence, as well as sentinel lymph node positivity, independent of traditional staging factors, and has been studied in more than 3,100 patient samples. Using tissue from the primary melanoma, the test measures the expression of 31 genes. The test has been validated in four archival risk of recurrence studies of 901 patients and five prospective risk of recurrence studies including more than 780 patients. Prediction of the likelihood of sentinel lymph node positivity has also been validated in two prospective multicenter study cohorts that included more than 1,400 patients. Impact on patient management plans for one of every two patients tested has been demonstrated in four multicenter and single-center studies including more than 560 patients. The consistent performance and accuracy demonstrated in these studies provides confidence in disease management plans that incorporate DecisionDx-Melanoma test results.

More information about the test and disease can be found at www.SkinMelanoma.com.

About Castle Biosciences

Castle Biosciences is a skin cancer diagnostics company dedicated to helping patients and their physicians make more informed decisions about treatment and follow-up care based on the individual molecular signature of the patient's tumor. The Company currently offers tests for patients with cutaneous melanoma (DecisionDx®-Melanoma, DecisionDx®-CMSeq; www.SkinMelanoma.com) and uveal melanoma (DecisionDx®-UM, DecisionDx®-PRAME and DecisionDx®-UMSeq; www.MyUvealMelanoma.com), with products in development for other underserved cancers, the most advanced of which is focused on patients with cutaneous squamous cell carcinoma. Castle Biosciences is based in Friendswood, Texas (Houston), and has laboratory operations in Phoenix, Arizona. More information can be found at www.CastleBiosciences.com.

DecisionDx-Melanoma, DecisionDx-CMSeq, DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UMSeq are the trademarks of Castle Biosciences, Inc. Any other trademarks are the property of their respective owners.


These press releases may also interest you

at 04:15
Machine-scale data protection provider Ionic today announced it is a launch integrator for Google Cloud's External Key Manager, a new offering that manages cloud risk and privacy by externalizing positive control over how cloud data, services and...

at 04:15
AliExpress, a global retail online marketplace under Alibaba Group, successfully wrapped up its 2019 48-hour 11.11 Global Shopping Festival. With buyers from over 200...

at 04:05
GOOGLE CLOUD NEXT--CloudBees, the enterprise DevOps leader powering the continuous economy, today announced an extension of its partnership with Google. As a Google Cloud Run launch partner, CloudBees will offer developers more flexibility in their...

at 04:05
Fortanix® Inc., the Runtime Encryption® company, today announced that it has collaborated with Google Cloud Platform (GCP) to integrate its newly announced External Key Manager service with the Fortanix Self-Defending Key Management Servicetm...

at 04:05
Sungrow, the global leading inverter solution supplier for renewables, today announced that its first 1500Vdc DC-Coupled PV plus energy storage system has connected to the 9MW/3.836MWh utility-scale storage project, which developed by 174 Power...

at 04:04
Google Cloud today announced that Vodafone, one of the world's leading telecom and technology services companies, has selected Google Cloud to host its strategic cloud platform for data analytics, business intelligence, and machine learning, called...



News published on 6 june 2019 at 07:05 and distributed by: